2001 Clinical Trials Patients Treatment 
Cannabis Law Report
MARCH 23, 2022
Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. However, our drug laws impede research and deny patients access to these highly effective medicines. There are a number of differences between PAP and current treatment approaches.
Cannabis Law Report
AUGUST 2, 2021
(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. ” About The Study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JANUARY 13, 2023
The fact that migraine is now ranked as the second leading cause of years lived with disability illustrates the magnitude of the negative impact of the disease to patients and their ability to function normally. A 2019 retrospective review of 316 patients found that medical cannabis improved the experience of 88.3% headaches per month.
The Cannigma
MAY 19, 2021
Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. Shutterstock).
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. The Need for Cannabis Education Tailored to Patient and Doctor.
Cannabis Law Report
MARCH 1, 2019
Natalie has worked with private hospitals and clinics in relation to medical malpractice claims, and assisted on cases involving medical devices product liability and clinical trials. But doctors and patients are not only facing administrative or prescribing hurdles – there’s also the cost. Legalisation.
Expert insights. Personalized for you.
52 
Let's personalize your content